Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 8Terminated 6Active not recruiting 2Unknown 1Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Burkitt Lymphoma 13Leukemia, Biphenotypic, Acute 9Leukemia, Myeloid, Acute 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Osteosarcoma 3Myelodysplastic Syndromes 3Lymphoma 3Breast Neoplasms 3Blastic Plasmacytoid Dendritic Cell Neoplasm 3Primary Myelofibrosis 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Leukemia, Large Granular Lymphocytic 2Hematologic Neoplasms 2Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Sarcoma, Ewing 1Renal Pelvis and Ureter Urothelial Carcinoma 1Recurrence 1Polycythemia Vera 1Pathologic Complete Response 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1Mouth Neoplasms 1Meningeal Neoplasms 1

Interventions

fludarabine 4Specimen Handling 2Cytarabine 2Cyclophosphamide 2trametinib 1thymoglobulin 1merphos 1imetelstat 1hydrocortisone hemisuccinate 1fludarabine phosphate 1Watchful Waiting 1Spinal Puncture 1Rituximab 1Methotrexate 1Melphalan 1Levetiracetam 1Leucovorin 1Injections 1Hydrocortisone 1Hematopoietic Stem Cell Transplantation 1GRN163L peptide 1Busulfan 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myelomonocytic, Juvenile × Methotrexate × Clear all
NCT06247787 2026-04-20

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Children's Oncology Group

Phase 1 Recruiting
36 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡